stoxline Quote Chart Rank Option Currency Glossary
  
Actinium Pharmaceuticals, Inc. (ATNM)
1.555  0.025 (1.63%)    05-16 12:57
Open: 1.515
High: 1.595
Volume: 110,058
  
Pre. Close: 1.53
Low: 1.51
Market Cap: 49(M)
Technical analysis
2025-05-16 12:15:00 PM
Short term     
Mid term     
Targets 6-month :  1.91 1-year :  2.23
Resists First :  1.63 Second :  1.91
Pivot price 1.47
Supports First :  1.32 Second :  1.12
MAs MA(5) :  1.52 MA(20) :  1.42
MA(100) :  1.3 MA(250) :  2.83
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  69.3 D(3) :  69
RSI RSI(14): 57.7
52-week High :  9.94 Low :  1.02
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ATNM ] has closed below upper band by 24.1%. Bollinger Bands are 29.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.54 - 1.55 1.55 - 1.56
Low: 1.38 - 1.39 1.39 - 1.4
Close: 1.52 - 1.53 1.53 - 1.54
Company Description

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.

Headline News

Fri, 16 May 2025
Actinium Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - ATNM - WV News

Thu, 15 May 2025
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - May 27, 2025 Deadline to Join - Contact The Gross Law Firm - WV News

Wed, 14 May 2025
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and SoundHound and Encourages Investors to Contact the Firm - TradingView

Mon, 12 May 2025
ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit - PR Newswire

Mon, 12 May 2025
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM - PR Newswire

Fri, 09 May 2025
ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
AMEX
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 31 (M)
Held by Insiders 3.037e+007 (%)
Held by Institutions 2 (%)
Shares Short 2,470 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -4.648e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -57 %
Return on Assets (ttm) 665.4 %
Return on Equity (ttm) -31 %
Qtrly Rev. Growth 81000 %
Gross Profit (p.s.) 0
Sales Per Share -586.4
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.6 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -34 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0.16
Stock Dividends
Dividend 0
Forward Dividend 2.22e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android